April 22, 2025 3:00–3:20 PM
Strategy 1
GeneVentiv's AAV8.FVa gene therapy is the first universal gene therapy for all hemophilias and the first to treat inhibitor patients.
GeneVentiv's AAV8.FVa gene therapy is the first universal gene therapy for all hemophilias and the first to treat inhibitor patients.